お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
384190

世界の皮膚科市場:2028年までの予測

The Global Dermatology Market to 2028

出版日: | 発行: GMR Data Ltd | ページ情報: 英文 180 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.68円
世界の皮膚科市場:2028年までの予測
出版日: 2018年06月04日
発行: GMR Data Ltd
ページ情報: 英文 180 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の皮膚疾患治療薬 (処方薬) 市場は、2017年に384億米ドルとなりました。同市場は、2018年には441億米ドルに達すると予測されています。

当レポートでは、世界の皮膚疾患治療薬の市場について調査分析し、皮膚疾患の各種区分、現在の治療法、新薬の研究開発の動向、市場規模の推移と予測、主要企業のプロファイル、専門家の見解などをまとめ、お届けいたします。

第1章 エグゼクティブサマリー

第2章 世界の皮膚科市場における現在の動向・発展

  • 現在の動向、課題および発展
  • 皮膚科における生物製剤
  • M&A

第3章 世界の皮膚科治療薬市場・予測

  • 世界市場の概要
  • 世界の皮膚科治療薬市場:種類別

第4章 世界の尋常性座瘡 (にきび) の処方薬市場・予測

  • 種類と症状
  • 発症率と有病率
  • 主な動向
  • 現在の処方治療
  • 市場規模と予測
  • 上市済み治療薬の市場と予測
  • 第III相パイプラインの予測
  • 第II相パイプラインの予測
  • 競合分析

第5章 世界の乾癬の処方薬市場・予測

  • 種類と症状
  • 発症率と有病率
  • 主な動向
  • 現在の処方治療
  • 市場規模と予測
  • 上市済み治療薬の市場と予測
  • 第III相パイプラインの予測
  • 第II相パイプラインの予測
  • 競合分析

第6章 世界の脱毛症の処方薬市場・予測

  • 種類と症状
  • 発症率と有病率
  • 主な動向
  • 現在の処方治療
  • 市場規模と予測
  • 上市済み治療薬の市場と予測
  • 第III相パイプラインの予測
  • 第II相パイプラインの予測
  • 競合分析

第7章 世界の皮膚癌の処方薬市場・予測

  • 種類と症状
  • 発症率と有病率
  • 主な動向
  • 現在の処方治療
  • 市場規模と予測
  • 上市済み治療薬の市場と予測
  • 第III相パイプラインの予測
  • 第II相パイプラインの予測
  • 競合分析

第8章 世界の皮膚感染症の処方薬市場・予測

  • 種類と症状
  • 発症率と有病率
  • 主な動向
  • 現在の処方治療
  • 市場規模と予測
  • 上市済み治療薬の市場と予測
  • 第III相パイプラインの予測
  • 第II相パイプラインの予測
  • 競合分析

第9章 世界のアトピー性皮膚炎の処方薬市場・予測

  • 種類と症状
  • 発症率と有病率
  • 主な動向
  • 現在の処方治療
  • 市場規模と予測
  • 上市済み治療薬の市場と予測
  • 第III相パイプラインの予測
  • 第II相パイプラインの予測
  • 競合分析

第10章 世界の酒さの処方薬市場・予測

  • 種類と症状
  • 発症率と有病率
  • 主な動向
  • 現在の処方治療
  • 市場規模と予測
  • 上市済み治療薬の市場と予測
  • 競合分析

第11章 世界の皮膚科部門における主要国市場

  • 米国の皮膚科治療薬市場・予測
  • 英国の皮膚科治療薬市場・予測
  • フランスの皮膚科治療薬市場・予測
  • ドイツの皮膚科治療薬市場・予測
  • スペインの皮膚科治療薬市場・予測
  • イタリアの皮膚科治療薬市場・予測
  • 日本の皮膚科治療薬市場・予測
  • その他の地域の皮膚科治療薬市場・予測

第12章 専門家の見解

付録

目次
Product Code: DERMA28

The global dermatological (prescription) drugs market was valued at $38.4bn in 2017, GMR Data forecast that this will rise to $44.1bn across 2018.

The third in a series of biennial Dermatology reports sees GMR Data again interview industry experts to produce a market leading report that dissects and investigates the key questions in the Global Dermatology Market across the next decade.

GMR Data forecasts that the global dermatology (prescription) drugs market will report a CAGR of 6.4% across 2018 and 2028.

Of the seven dermatological drugs types / segments highlighted in the report, Atopic Dermatitis and Skin Cancer are estimated to display the highest growth rates (10-year CAGR) of 12.8% and 9.2% respectively.

GMR Data attributes this growth to a change in treatment modalities of the mentioned dermatological diseases. The new treatment modality widely uses a targeted approach of 'biological' drugs that are specific, highly efficacious and result in high QALY; for instance - MoAbs or monoclonal antibodies witnessed higher adoption rates in Atopic Dermatitis.

5 Reasons why you must read this report today:

  • 1. Dermatology drug manufacturers are enjoying higher revenues than ever before in this niche market and with increasing prevalence of skin diseases, this will continue across the next decade.
  • 2. A number of leading drugs are set to come off of patent across the forecast period.
  • 3. Pipeline products addressing areas of unmet clinical need, especially in the acne, skin infections and skin cancer markets with the potential to become blockbusters, will launch during the forecast period.
  • 4. Understanding the areas of the market in which growth will occur allows for a more tailored approach to expansion, increasing the chances of success.
  • 5. GMR Data's report gives an in depth and independent view of the leading companies in the dermatology drugs market, ensuring you have all the information needed when moving forward.

Included in the report is analysis of the leading companies and geographies in the dermatology drugs market, as well as of the opportunities and threats facing manufacturers. The report has forecasts for all key submarkets in the market as well as for the leading drugs.

The primary companies in the market are studied with pipeline products and merger & acquisitions in relation to the dermatology sector.

This independent, 180 page report guarantees you will remain better informed than your competition. With over 150 tables and figures examining the dermatology drugs market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leaders market revenue forecasts as well as analysis to 2028, which keeps your knowledge that one step ahead, helping you to succeed. This report is essential reading for you or anyone in the pharmaceutical or health care sectors. Purchasing this report today will help you to recognise those important market opportunities and understand the possibilities there.

Table of Contents

1 - Executive Summary

  • 1.1 Executive Summary
  • 1.2 Report Description
  • 1.3 Market Segmentation
  • 1.4 Research Methodology

2 - Current Trends & Developments in the Global Dermatology Market

  • 2.1 Current Trends, Challenges & Developments
    • 2.1.1. Historic Limited Economic Potential - Changed with Introduction of Biologics
    • 2.1.2. Stringent Regulatory Norms for Clearance
    • 2.1.3. Switch from Prescription to OTC
    • 2.1.4. Difficulty with Combination Drugs
  • 2.2 Biologics in Dermatology
  • 2.3 Mergers and Acquisitions

3 - Global Dermatological Drugs Market & Forecast, 2018 - 2028

  • 3.1 Global Market Overview
  • 3.2 Global Dermatological Drugs Market by Type

4 - Global Acne Vulgaris Prescription Drugs Market & Forecast, 2018 - 2028

  • 4.1 Types and Symptoms of Acne Vulgaris
  • 4.2 Incidence and Prevalence of Acne Vulgaris
  • 4.3 Key Trends in the Global Acne Vulgaris Market
  • 4.4 Current Prescription (rx) Treatments for Acne Vulgaris
  • 4.5 Global Acne Vulgaris Market Size &Forecast, 2018 - 2028
  • 4.6 Current Marketed Drugs & Forecast
    • 4.6.1. Solodyn Market and Forecast
    • 4.6.2. Doryx Market and Forecast
    • 4.6.3. Epiduo Market and Forecast
  • 4.7 Acne Vulgaris - Phase III Drugs Pipeline Forecast
    • 4.7.1. Onexton (Valeant)
    • 4.7.2. Epiduo Forte (Galderma)
    • 4.7.3. Sarecycline (Actavis)
  • 4.8 Acne Vulgaris - Phase II Drugs Pipeline Forecast
    • 4.8.1. DRM01 (Dermira)
    • 4.8.2. FMX101 (Foamix)
    • 4.8.3. SB204 (Novan Therapeutics)
    • 4.8.4. SEB002 (Sebacia)
    • 4.8.5. MTC896 (Mimetica)
  • 4.9 Competitive Analysis in the Acne Vulgaris Market
    • 4.9.1. Valeant Pharmaceuticals
    • 4.9.2. Dermira
    • 4.9.3. Paratek Pharmaceuticals
    • 4.9.4. Mayne Pharma

5 - Global Psoriasis Prescription Drugs Market & Forecast, 2018 - 2028

  • 5.1 Types & Symptoms of Psoriasis
  • 5.2 Incidence & Prevalence of Psoriasis
  • 5.3 Key Trends in the Global Psoriasis Market
  • 5.4 Current Prescription (Rx) Treatments for Psoriasis
  • 5.5 Global Psoriasis Market Size & Forecast, 2018 - 2028
  • 5.6 Current Marketed Drugs & Forecast
    • 5.6.1. Stelara (Psoriasis) Market and Forecast
    • 5.6.2. Enbrel (Psoriasis) Market and Forecast
    • 5.6.3. Humira (Psoriasis) Market and Forecast
    • 5.6.4. Otezla (Psoriasis) Market and Forecast
    • 5.6.5. Cosentyx (Psoriasis) Market and Forecast
    • 5.6.6. Taltz (Psoriasis) Market and Forecast
    • 5.6.7. Piclidenoson (Psoriasis) Market and Forecast
  • 5.7 Psoriasis - Phase III Drugs (Injectable Biologics) Pipeline Forecast
    • 5.7.1. BI 655066 (Boehringer Ingelheim)
    • 5.7.2. Guselkumab (Janssen)
    • 5.7.3. Tildrakizumab (Sun Pharma)
  • 5.8 Psoriasis - Phase III Drugs (Injectable Biologics) Pipeline Forecast
    • 5.8.1. Cimzia (UBC)
    • 5.8.2. Brodalumab (Astra-Zeneca/Valeant)
  • 5.9 Psoriasis - Phase II Drugs (Injectable Biologics) Pipeline Forecast
    • 5.9.1. Tregalizumab (Biotest AG)
    • 5.9.2. Namilumab (Takeda Pharmaceuticals)
    • 5.9.3. IMO-8400 (Idera Pharmaceuticals)
  • 5.10 Psoriasis - Phase II (10) Drugs (Orally Administered) Pipeline Forecast
  • 5.11 Competitive Analysis In Psoriasis Market
    • 5.11.1. Celgene Corporation
    • 5.11.2. Novartis
    • 5.11.3. Can-Fite BioPharma

6 - Global Alopecia Prescription Drugs Market & Forecast, 2018 - 2028

  • 6.1 Types and Symptoms of Alopecia
  • 6.2 Incidence and Prevalence Of Alopecia
  • 6.3 Key Trends in The Global Alopecia Market
  • 6.4 Current Prescription (Rx) Treatments for Alopecia
  • 6.5 Global Alopecia Market Size And Forecast, 2018 - 2028
  • 6.6 Current Marketed Drugs and Forecast
    • 6.6.1. Propecia Market and Forecast
  • 6.7 Alopecia - Phase III Drugs Pipeline Forecast
    • 6.7.1. Bimatoprost (Allergan)
    • 6.7.2. SM04554 (Samumed)
  • 6.8 alopecia - phase II (2) Drugs Pipeline Forecast
  • 6.9 Competitive Analysis In Alopecia Market
    • 6.9.1. Merck
    • 6.9.2. Samumed
    • 6.9.3. Concert Pharmaceuticals

7 - Global Skin Cancer Prescription Drugs Market & Forecast, 2018 - 2028

  • 7.1 Types and Symptoms of Skin Cancer
  • 7.2 Incidence and Prevalence of Skin Cancer
  • 7.3 Key Trends in the Global Skin Cancer Market
  • 7.4 Current Prescription (Rx) Treatments for Skin Cancer
  • 7.5 Global Skin Cancer Market Size and Forecast, 2018 - 2028
  • 7.6 Current Marketed Drugs and Forecast
    • 7.6.1. Yervoy Market and Forecast
    • 7.6.2. Zelboraf + Cotellic Market and Forecast
    • 7.6.3. Tafinlar + Mekinist Market and Forecast
    • 7.6.4. Keytruda Market and Forecast
    • 7.6.5. Opdivo, Opdivo + Yervoy Market and Forecast
    • 7.6.6. Imlygic Market and Forecast
    • 7.6.7. Erivedge Market and Forecast
    • 7.6.8. Odomzo Market and Forecast
  • 7.7 Skin Cancer - Phase III (12) Drugs Pipeline Forecast
  • 7.8 Skin Cancer - Phase II (53) Drugs Pipeline Forecast
  • 7.9 Competitive Analysis In Skin Cancer Market
    • 7.9.1. Roche Holding (Roche)
    • 7.9.2. Sun Pharmaceutical Industries

8 - Global Skin Infections Prescription Drugs Market & Forecast, 2018 - 2028

  • 8.1 Types and Symptoms of Skin Infections
  • 8.2 Incidence and Prevalence of Skin Infections
  • 8.3 Key Trends in the Global Skin Infections Market
  • 8.4 Current Prescription (Rx) Treatments for Skin Infections
  • 8.5 Global Skin Infections Market Size and Forecast, 2018 - 2028
  • 8.6 Current Marketed Drugs and Forecast - cSSSIS
    • 8.6.1. Cubicin Market and Forecast
    • 8.6.2. Zyvox Market and Forecast
    • 8.6.3. Sivextro Market and Forecast
    • 8.6.4. Orbactiv Market and Forecast
    • 8.6.5. Dalvance Market and Forecast
    • 8.6.6. Tygacil Market and Forecast
    • 8.6.7. Teflaro Market and Forecast
  • 8.7 Current Marketed Drugs and Forecast - Onychomycosis
    • 8.7.1. Kerydin Market and Forecast
    • 8.7.2. Jublia Market and Forecast
  • 8.8 Skin Infections - Phase III (11) Drugs (cSSSIS) Pipeline Forecast
  • 8.9 Skin Infections - Phase III (3) Drugs (Onychomycosis) Pipeline Forecast
  • 8.10 Skin Infections - Phase Ii (3) Drugs (Onychomycosis) Pipeline Forecast
  • 8.11 Competitive Analysis in the Skin Infections Market
    • 8.11.1. Novan Therapeutics

9 - Global Atopic Dermatitis Prescription Drugs Market & Forecast, 2018 - 2028

  • 9.1 Types and Symptoms of Dermatitis
  • 9.2 Incidence and Prevalence of Atopic Dermatitis
  • 9.3 Key Trends in the Dermatitis Market
  • 9.4 Current Prescription (Rx) Treatments for Dermatitis
  • 9.5 Global Atopic Dermatitis Market Size and Forecast, 2018 - 2028
  • 9.6 Current Marketed Drugs and Forecast
    • 9.6.1. Dupixent Market and Forecast
    • 9.6.2. Eucrisa Market and Forecast
  • 9.7 Atopic Dermatitis - Phase III Drugs Pipeline Forecast
    • 9.7.1. ZPL-389 (Ziarco Pharma)
    • 9.7.2. Nanocyclo (Immune Pharmaceuticals)
  • 9.8 Atopic Dermatitis - Phase II Drugs (Orally/Topically Administered) Pipeline Forecast
    • 9.8.1. Tofactinib/Xeljanz (Pfizer)
    • 9.8.2. ZPL-521 (Ziarco Pharma)
    • 9.8.3. OPA-15406 (Otsuka/Medimetriks)
    • 9.8.4. Upadacitinib (AbbVie)
    • 9.8.5. Baricitinib (Eli Lilly/Incyte)
  • 9.9 Atopic Dermatitis - Phase II Drugs (Injectable Moabs) Pipeline Forecast
    • 9.9.1. Bertilimumab (Immune Pharmaceuticals)
    • 9.9.2. Tralokinumab (Leo Pharma/Astra-Zeneca)
    • 9.9.3. Nemolizumab (Chugai Pharmaceuticals)
    • 9.9.4. Lebrikizumab (Roche/Genentech)
  • 9.10 Competitive Analysis in the Atopic Dermatitis Market
    • 9.10.1. Sanofi
    • 9.10.2. Pfizer
    • 9.10.3. Immune Pharmaceuticals

10 - Global Rosacea Prescription Drugs Market & Forecast, 2018 - 2028

  • 10.1 Types and Symptoms of Rosacea
  • 10.2 Incidence and Prevalence of Rosacea
  • 10.3 Key Trends in the Global Rosacea Market
  • 10.4 Current Prescription (Rx) Treatments for Rosacea
  • 10.5 Global Rosacea Market Size and Forecast, 2018 - 2028
  • 10.6 Current Marketed Drugs and Forecast
    • 10.6.1. Finacea Gel + Finacea Foam (Bayer/Foamix)
    • 10.6.2. Mirvaso (Galderma)
    • 10.6.3. Soolantra (Galderma)
    • 10.6.4. Oracea (Galderma)
    • 10.6.5. Rhofade (Allergan)
  • 10.7 Competitive Analysis in Rosacea Market
    • 10.7.1. Bayer
    • 10.7.2. Galderma (Nestle Skin Health)
    • 10.7.3. Allergan

11 - Key National Markets in the Global Dermatology Sector, 2018 - 2028

  • 11.1 U.S Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.2 U.K. Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.3 France Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.4 Germany Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.5 Spain Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.6 Italy Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.7 Japan Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.8 Row Dermatological Drugs Market and Forecast, 2018 - 2028
    • 11.8.1. Brazil Dermatological Drugs Market and Forecast, 2018 - 2028
    • 11.8.2. Russia Dermatological Drugs Market and Forecast, 2018 - 2028
    • 11.8.3. India Dermatological Drugs Market and Forecast, 2018 - 2028
    • 11.8.4. China Dermatological Drugs Market and Forecast, 2018 - 2028

12 - Expert Opinion

  • 12.1 Galderma
  • 12.2 Ranbaxy

Appendix: Skin Cancer - Phase III & Phase II Drugs Pipeline

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.